Novel insights into macrophage immunometabolism in nonalcoholic steatohepatitis

Int Immunopharmacol. 2024 Mar 18;131:111833. doi: 10.1016/j.intimp.2024.111833. Online ahead of print.ABSTRACTNonalcoholic steatohepatitis (NASH), an inflammatory subtype of nonalcoholic fatty liver disease (NAFLD), is characterized by liver steatosis, inflammation, hepatocellular injury and different degrees of fibrosis, and has been becoming the leading cause of liver-related morbidity and mortality worldwide. Unfortunately, the pathogenesis of NASH has not been completely clarified, and there are no approved therapeutic drugs. Recent accumulated evidences have revealed the involvement of macrophage in the regulation of host liver steatosis, inflammation and fibrosis, and different phenotypes of macrophages have different metabolic characteristics. Therefore, targeted regulation of macrophage immunometabolism may contribute to the treatment and prognosis of NASH. In this review, we summarized the current evidences of the role of macrophage immunometabolism in NASH, especially focused on the related function conversion, as well as the strategies to promote its polarization balance in the liver, and hold promise for macrophage immunometabolism-targeted therapies in the treatment of NASH.PMID:38503012 | DOI:10.1016/j.intimp.2024.111833
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Source Type: research